COMPARISON OF QUALITY OF LIFE IN PATIENTS WITH PCSK9 INHIBITORS VS. STATIN INTOLERANCE
Therapeutic Area: PCSK9 inhibitors Background: PCSK9 inhibitors (PCSK9i) reduce cardiovascular (CV) events and lower LDL levels by 60% when added to statin therapy in high-risk patients, but lack data regarding quality of life (QoL). QoL impacts patient compliance and clinical decision making. We so...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2023-03-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |